Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators
Pietro Ghezzi(Brighton and Sussex Medical School), Ettore Marubini(University of Milan), B. Trolli, A Rolfo, Ornella Gottardi, M.R. Giolito, F Peradotto, Gianpaolo Papaccio(University of Campania "Luigi Vanvitelli"), C. Epifani, Giovanna Cavazzini(University of Padua), E Ghislandi, N. Tavoni, A Santini, Guido Gini(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), A. Richetti, Elisa Locatelli, L. Armaroli, M. Majno, P. Viola, Marco Fumagalli, Giacomo Paolo Vaudano, O. Nascimben, Alberto Zaniboni(Fondazione Poliambulanza Istituto Ospedaliero), Francesco Schittulli, L Galletto, D. Perroni(Florence (Netherlands)), G Marini, G. Ambrosini, Marco Monti, R. Busolin, F Smerieri, Lucia Busana, M Sussio, S. Magnanini, Alfonso M. Pluchinotta, C Confalonieri, Monica Indelli, G. Gritti, F Berardi, M. Rinaldini, F. Testare, M. Molteni, Enrico Aitini, C. D’Amico, L. Isa, D. Cosentino, T Pedicini, Marco Braga(Centro de Tecnologia Mineral), Marzia De Biasio, G. Di Biagio
Cited by 95
Related Papers
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Clinical Relevance of Biomarkers of Oxidative Stress
|Antioxidants and Redox Signaling|2015|884
Dietary Factors and Risk of Breast Cancer: Combined Analysis of 12 Case--Control Studies
|JNCI Journal of the National Cancer Institute|1990|756